Farruggia Piero, Giugliano Emilia, Russo Delia, Trizzino Angela, Lorenzatti Roberta, Santoro Alessandra, D'Angelo Paolo
*Pediatric Hematology and Oncology Unit, Oncology Department, A.R.N.A.S. Civico, Di Cristina and Benfratelli Hospitals ‡Hematology I, A.O. Villa Sofia-Cervello, Palermo †Molecular Biology Laboratory, Department of Clinical and Biologic Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
J Pediatr Hematol Oncol. 2014 Jan;36(1):e28-30. doi: 10.1097/MPH.0b013e31827e6386.
Hypereosinophilic syndromes in children are rare disorders traditionally characterized by an eosinophil count exceeding 1,500/mm³ on at least 2 occasions or evidence of tissue eosinophilia associated with symptoms and marked blood eosinophilia, lacking any secondary cause (such as infections, allergic disease, chemical-induced eosinophilia, hypoadrenalism, cancer). Until now there have only been 3 reported cases of pediatric FIP1L1-PDGFRα-positive hypereosinophilic syndromes. We describe a fourth patient, a white 14-year-old boy, the third treated with imatinib.
儿童嗜酸性粒细胞增多综合征是罕见疾病，传统上其特征为至少两次嗜酸性粒细胞计数超过1500/mm³，或有组织嗜酸性粒细胞增多的证据，伴有症状和明显的血液嗜酸性粒细胞增多，且无任何继发原因（如感染、过敏性疾病、化学物质诱导的嗜酸性粒细胞增多、肾上腺功能减退、癌症）。到目前为止，仅报告了3例儿童FIP1L1-PDGFRα阳性嗜酸性粒细胞增多综合征病例。我们描述了第四例患者，一名14岁白人男孩，是接受伊马替尼治疗的第三例患者。
